Table 1.
Demographics of interviewed pharmacists, their pharmacies and the drugs, for which actionable recommendations were received before being interviewed.
| Characteristics Interviewed Pharmacist (n = 15) | |
|---|---|
| Age (years) | |
| Mean (SD, range) | 38.5 (9.9, 25–59) |
| Gender | |
| Female | 53.3% |
| Work experience (years) | |
| Mean (SD, range) | 12.9 (9.0, 0.5–30.0) |
| Role in pharmacy | |
| Managing pharmacist | 73.3% |
| Supporting pharmacist | 6.7% |
| Community pharmacy specialist in training | 20.0% |
| Self-reported pharmacogenomic knowledge (scale 1–5) | |
| Mean (SD, range) | 3.3 (0.6, 2–4) |
| Self-reported belief in effect of pre-emptive pharmacogenomic testing (scale 1–5) | |
| Mean (SD, range) | 4.1 (0.6, 3–5) |
| Completed PGx e-learning? | |
| Yes, completely | 20% |
| Yes, partly | 13.3% |
| No | 66.7% |
| When partly, what section of the e-learning did you complete? | |
| The information videos | 13.3% |
| Number of recommendations received at time of interview | |
| Mean (SD, range) | 3.5 (2.5, 2–11) |
| Participation in previous PGx study | |
| Yes | 5 (33%) |
| Pharmacy characteristics (n = 13) 1 | |
| Number of patients | |
| <5000 | 7.7% |
| 5000–7500 | - |
| 7500–10,000 | 46.2% |
| >10,000 | 46.2% |
| Full-time equivalents of pharmacists | |
| ≤1 FTE | 30.8% |
| >1 and ≤2 FTE | 61.5% |
| >2 and ≤3 FTE | 7.7% |
| Pharmacy organization | |
| Independent | 23.1% |
| Franchise | 23.1% |
| Pharmacy group | 53.8% |
| Located in a healthcare center? | |
| Yes | 38.5% |
| Top 5 drugs for which actionable recommendations were received by interviewed pharmacists | |
| Simvastatin | 25 (27.2%) |
| Metoprolol | 22 (23.9%) |
| Tramadol | 11 (12.0%) |
| Amitriptyline | 8 (8.7%) |
| Atorvastatin | 5 (5.4%) |
Abbreviations used: SD = standard deviation, FTE = full time equivalent. 1 Multiple pharmacists worked in the same pharmacy.